医学
放射外科
流血
颅内动静脉畸形
回顾性队列研究
动静脉畸形
不利影响
入射(几何)
脑出血
放射科
队列
外科
脑血管造影
核医学
蛛网膜下腔出血
血管造影
内科学
放射治疗
光学
物理
作者
Georgios Mantziaris,Bardia Hajikarimloo,Salem M Tos,Stylianos Pikis,Jason W. Chan,Penny K. Sneed,Michael W. McDermott,Zachary Seymour,Inga S. Grills,Ahmed M. Nabeel,Wael A. Reda,Sameh R. Tawadros,Khaled Abdelkarim,Amr M. N. El-Shehaby,Reem M. Emad,Othman Bin-Alamer,L. Dade Lunsford,Ajay Niranjan,Selçuk Peker,Yavuz Samancı
出处
期刊:Neurosurgery
[Lippincott Williams & Wilkins]
日期:2025-08-11
标识
DOI:10.1227/neu.0000000000003682
摘要
BACKGROUND AND OBJECTIVES: Single-session stereotactic radiosurgery (SRS) has limited role for large arteriovenous malformations (AVM). Volume-staged SRS (VS-SRS) is used to optimize outcomes, but studies reporting results are limited. METHODS: This multicenter retrospective cohort of 378 patients from 21 centers reports results of VS-SRS for the entire AVM nidus. We report favorable outcome, obliteration, hemorrhage, and permanent symptomatic adverse radiation effect rates. RESULTS: The median age was 31 years (IQR: 19-44) at the first volume stage, with patients treated in 2–4 stages. The median total nidus volume was 21 cm 3 (IQR: 13.9-30.1 cm 3 ), and a median prescription dose of 17 Gy (IQR: 16-18 Gy) was used. The median radiographic and clinical follow-up were 48 and 55 months, respectively. Seventy-seven patients (20.4%) had a favorable outcome, with the 3-year and 5-year rates being 3.9% and 18%, respectively. 127 patients (33.6%) achieved obliteration, with the 3-year and 5-year rates being 6.8% and 26%, respectively. Obliteration rates of AVMs <15 cm 3 were 81% and 31%, respectively. The latency period hemorrhage incidence rate was 3.02 cases per 100 patient-years; 52 patients (13.8%) had a bleed. Seventy-two patients (19%) had symptomatic adverse radiation effect; in 38 patients (10.1%), these were permanent. Total nidus volume, prescription dose at first stage, diffuse nidus, and prior hemorrhage were all independent affecting outcome rates. CONCLUSION: VS-SRS can be used to treat large AVMs as a standalone treatment. Obliteration rates and favorable outcomes are lower than that with smaller AVMs, and repeat treatment is often required. Optimizing treatment plans, by increasing prescription doses, reducing treatment volume at each stage, and increasing the number of stages, may lead to better outcomes.